PDF(Pubmed)
Abstract：
Mucosal vaccination strategies are easier to implement than others in large-scale poultry farming. However, the adjuvants that are approved for veterinary use, which are predominantly aluminum- and oil-emulsion-based adjuvants, are not suitable for mucosal vaccination and carry a risk of adverse reactions. In this study, we engineered a novel Lactobacillus plantarum NC8 strain that co-expresses chicken interleukin-2 (IL-2) and IL-17B, which we designated NC8-ChIL2-17B, and evaluated its potential as an oral immunoadjuvant. The immunomodulatory properties of NC8-ChIL2-17B were evidenced by its ability to activate macrophages and inhibit the proliferation of infectious bronchitis virus (IBV) in vitro. We then confirmed its immunoadjuvant activity in vivo by orally administering NC8-ChIL2-17B along with a commercial IBV vaccine to chicks. The results indicated that NC8-ChIL2-17B enhanced the immune response elicited by the IBV vaccine and increased the levels of IBV-specific IgG and sIgA antibodies produced in response to IBV infection. Additionally, administration of NC8-ChIL2-17B promoted weight gain and beneficially modulated the gut microbiota, resulting in improved chicken performance. These findings suggest that oral administration of NC8-ChIL2-17B is a promising strategy to enhance the immune efficacy of the IBV vaccine in chickens, offering an efficacious alternative adjuvant.
摘要：
在大规模家禽养殖中，粘膜疫苗接种策略比其他策略更容易实施。然而,批准用于兽医的佐剂，主要是基于铝和油乳液的佐剂，不适合粘膜疫苗接种，并有不良反应的风险。在这项研究中,我们设计了一个新的植物乳杆菌NC8菌株，共表达鸡白细胞介素-2（IL-2）和IL-17B，我们命名为NC8-ChIL2-17B，并评估了其作为口服免疫佐剂的潜力。NC8-ChIL2-17B的免疫调节特性通过其在体外激活巨噬细胞和抑制感染性支气管炎病毒（IBV）增殖的能力得到证明。然后,我们通过向雏鸡口服施用NC8-ChIL2-17B以及商业IBV疫苗来证实其体内免疫佐剂活性。结果表明,NC8-ChIL2-17B增强了由IBV疫苗引发的免疫应答,并增加了响应于IBV感染而产生的IBV特异性IgG和sIgA抗体的水平。此外,NC8-ChIL2-17B的给药促进体重增加并有益地调节肠道微生物群，从而改善鸡的性能。这些发现表明，口服NC8-ChIL2-17B是增强鸡IBV疫苗免疫功效的有希望的策略，提供有效的替代佐剂。
